Abstract:Hypoxia is a common feature of solid tumours affecting their biology and response to therapy. One of the main transcription factors activated by hypoxia is hypoxia-inducible factor (HIF), which regulates the expression of genes involved in various aspects of tumourigenesis including proliferative capacity, angiogenesis, immune evasion, metabolic reprogramming, extracellular matrix (ECM) remodelling, and cell migration. This can negatively impact patient outcomes by inducing therapeutic resistance. The importance of hypoxia is clearly demonstrated by continued research into finding clinically relevant hypoxia biomarkers, and hypoxia-targeting therapies. One of the problems is the lack of clinically applicable methods of hypoxia detection, and lack of standardisation. Additionally, a lot of the methods of detecting hypoxia do not take into consideration the complexity of the hypoxic tumour microenvironment (TME). Therefore, this needs further elucidation as approximately 50% of solid tumours are hypoxic. The ECM is important component of the hypoxic TME, and is developed by both cancer associated fibroblasts (CAFs) and tumour cells. However, it is important to distinguish the different roles to develop both biomarkers and novel compounds. Fibronectin (FN), collagen (COL) and hyaluronic acid (HA) are important components of the ECM that create ECM fibres. These fibres are crosslinked by specific enzymes including lysyl oxidase (LOX) which regulates the stiffness of tumours and induces fibrosis. This is partially regulated by HIFs. The review highlights the importance of understanding the role of matrix stiffness in different solid tumours as current data shows contradictory results on the impact on therapeutic resistance. The review also indicates that further research is needed into identifying different CAF subtypes and their exact roles; with some showing pro-tumorigenic capacity and others having anti-tumorigenic roles. This has made it difficult to fully elucidate the role of CAFs within the TME. However, it is clear that this is an important area of research that requires unravelling as current strategies to target CAFs have resulted in worsened prognosis. The role of immune cells within the tumour microenvironment is also discussed as hypoxia has been associated with modulating immune cells to create an anti-tumorigenic environment. Which has led to the development of immunotherapies including PD-L1. These hypoxia-induced changes can confer resistance to conventional therapies, such as chemotherapy, radiotherapy, and immunotherapy. This review summarizes the current knowledge on the impact of hypoxia on the TME and its implications for therapy resistance. It also discusses the potential of hypoxia biomarkers as prognostic and predictive indictors of treatment response, as well as the challenges and opportunities of targeting hypoxia in clinical trials.

Tumor hypoxia: From basic knowledge to therapeutic implications

Hypoxia Signaling in Cancer: Implications for Therapeutic Interventions

Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies

Role of hypoxia in the tumor microenvironment and targeted therapy

Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications

The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions

Hypoxic tumor microenvironment: Implications for cancer therapy

Current Advances in Modulating Tumor Hypoxia for Enhanced Therapeutic Efficacy.

Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways

Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies

The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies

Hypoxia: Intriguing Feature in Cancer Cell Biology

The role of hypoxic microenvironment in the progress of tumor

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

Tumor hypoxia and heterogeneity: Challenges and opportunities for the future

Research progress on tumor hypoxia-associative nanomedicine

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

Hypoxia and the Tumor Microenvironment

Molecular responses to hypoxia in tumor cells

Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours